Answers are grounded in this paper and cite their sources.
Review evaluates antihypertensive therapy and dose adjustments in CKD patients, suggesting improvements in managing blood pressure and preventing complications.
Hypertension both causes and is caused by chronic kidney disease (CKD), requiring cautious management strategies to prevent renal and cardiovascular issues. To assure safety and reach a blood pressure (BP) goal of less than 130/80 mmHg, the current study aims to evaluate antihypertensive therapy in participants with chronic kidney disease (CKD), with particular attention to drug selection, combination regimens, dose adjustment, and individual characteristics. Identification of ideal first-line therapy, determination of the best mix of effective combinations, and solutions to issues such as drug-resistant hypertension and harmful drug interactions are among the priority objectives. Due to their renoprotective and antiproteinuric effects, ACEIs and ARBs are necessary in CKD. CCBs, diuretics, or aldosterone antagonists as part of combination therapy reduce blood pressure. Proteinuria is reduced, and newer drugs, along with sodium limitation, improve treatment efficacy. The present review provides dose modification and appropriate antihypertensive drug options for individuals with chronic kidney disease.
No takes yet. Share an insight, caveat, or question.
SHELKE et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: